Genentech announced positive topline data from two phase 3 trials, POLYP 1 and POLYP 2, evaluating Xolair (omalizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to intranasal corticosteroids.
A new PDUFA date for the treatment is now June 21, 2019; the FDA did not request additional studies from the Company.
According to the results of a recently published systematic review, the combination of intranasal azelastine plus fluticasone is more effective in reducing symptom scores in patients with allergic rhinitis (AR) than either component alone.
Regeneron and Sanofi announced that the Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP). The sBLA included data from two phase 3 randomized, double-blind, placebo-controlled trials (SINUS-24…
Patients with chronic rhinosinusitis with nasal polyps experienced improvements in endoscopic, radiologic, and clinical outcomes when treated with dupilumab as add-on therapy to intranasal mometasone furoate.
Dupilumab is generally well tolerated and improves health-related quality of life associated with rhinoconjunctivitis in patients with uncontrolled moderate to severe asthma with comorbid allergic rhinitis.
This article is part of MPR‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019. SAN FRANCISCO —…
Twice daily GSP301, a fixed-dose nasal spray containing 665µg olopatadine hydrochloride and 25µg mometasone furoate, offers a rapid onset of action, is well tolerated, and is associated with noticeable improvements in ocular symptoms in patients with seasonal allergic rhinitis.
Certain intranasal corticosteroids (INCS) may place patients with allergic rhinitis at a higher risk for epistaxis, according to a study published in Otolaryngology-Head and Neck Surgery.
Tivic Health Systems announced that ClearUP Sinus Pain Relief has been cleared by the Food and Drug Administration (FDA) for the treatment of sinus pain due to allergic rhinitis, or hay fever, in adults aged ≥18 years.
